Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Last week, a New York Times article by Elisabeth Rosenthal accused the medical industry of, "borrowing business models from technology companies like Apple," pointing out that "the captive audience of Type 1 diabetics has spawned lines of high-priced gadgets and disposable accoutrements."
"A steady stream of new models and updates often offer dubious improvement," writes Rosenthal, "colored pumps; talking, bilingual meters; sensors reporting minute-by-minute sugar readouts."
Sernova, however, is a clinical stage company developing a medical technology capable of disrupting the current market for Type 1 diabetes treatment and may reduce costs for patients and insurance providers while improving patient quality of life.
http://www.marketwatch.com/story/new-diabetes-therapy-to-replace-insulin-injections-2014-04-24
"A steady stream of new models and updates often offer dubious improvement," writes Rosenthal, "colored pumps; talking, bilingual meters; sensors reporting minute-by-minute sugar readouts."
Sernova, however, is a clinical stage company developing a medical technology capable of disrupting the current market for Type 1 diabetes treatment and may reduce costs for patients and insurance providers while improving patient quality of life.
http://www.marketwatch.com/story/new-diabetes-therapy-to-replace-insulin-injections-2014-04-24
